AwesomeCapital: Vanda Phase III VQW-765 trial in adults with social anxiety disorder misses primary endpoint

Thursday, October 15, 2026

Vanda Phase III VQW-765 trial in adults with social anxiety disorder misses primary endpoint

and program put on hold pending further data analysis

https://finviz.com/stock?t=VNDA&p=d

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)